Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Myeloid 1Genitourinary 1Classical hematology 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Cytopenia 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced Cancer 1

Interventions

Cisplatin 3202Cyclophosphamide 3195Carboplatin 2977Radiotherapy 2790Paclitaxel 2718Gemcitabine 2572pembrolizumab 2384Bevacizumab 2209Docetaxel 2199Fluorouracil 1851Capecitabine 1831Oxaliplatin 1742Dexamethasone 1605Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1387Etoposide 1346Irinotecan 1248Leucovorin 1226Drug Therapy 1205Cytarabine 1130Pemetrexed 1076fludarabine 1063Specimen Handling 1016Vincristine 964Cetuximab 945Trastuzumab 944Prednisone 941Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
IDO-1 inhibitor LY3381916 × Clear all
NCT03335540 2022-09-26

ADVISE

Bristol-Myers Squibb

Phase 1 Completed
20 enrolled

Advanced Cancer

NCT03343613 2020-06-09

A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors

Eli Lilly and Company

Phase 1 Terminated
60 enrolled
BreastGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Triple Negative Breast Neoplasms

NCT01822691 2016-01-18

Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
15 enrolled 8 charts
Classical hematologyMyeloidOther hematologic neoplasm

Cytopenia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡